Clinical Trials · NCT05689372
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- Phase
- N/A
- Recruitment status
- Enrolling By Invitation
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 600
- Start date
- Feb 2026
- Locations
- 1 site, South Korea
- Primary endpoint
- Number (incidence) of adverse events (AEs)